drugset / Trial / NCT04984434
Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This trial is a Multiple center, Open-label, dose escalation Phase Ⅰ clinical study. The purpose is to evaluate the safety and tolerability of F182112 when infused intravenously (IV) and determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of F182112 when infused IV.
Timeline
- Start
- 2021-07-30
- Primary completion
- 2023-07-30
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F182112 | Unknown | 0.01 ug/kg | Intravenous |
| Subject | F182112 | Unknown | 0.1 ug/kg | Intravenous |
| Subject | F182112 | Unknown | 0.3 ug/kg | Intravenous |
| Subject | F182112 | Unknown | 1 ug/kg | Intravenous |
| Subject | F182112 | Unknown | 3 ug/kg | Intravenous |
| Subject | F182112 | Unknown | 10 ug/kg | Intravenous |
| Subject | F182112 | Unknown | 20 ug/kg | Intravenous |
| Subject | F182112 | Unknown | 30 ug/kg | Intravenous |